Fraser Murray
InvestorHead of Scientific Evaluation at Advent Life Sciences
About
Fraser Murray is a drug discovery specialist and entrepreneur with nearly 30 years of experience in early drug development across pharma and biotech. In addition to serving as Head of Scientific Evaluation at Advent Life Sciences, he is CEO of portfolio company Pheno Therapeutics, and previously led Pandeia Therapeutics (acquired in December 2022), Chronos Therapeutics, and Polleo Pharma. He began his career at Merck's Neuroscience Research Centre and held roles at AstraZeneca and Shire; he studied Immunology and Pharmacology at the University of Strathclyde, earned a PhD in Neuropharmacology at the University of London, and completed an executive MBA at Alliance Manchester Business School.
Contact· self-published, not guessed
Invests in
Biotech
Investments
Investor
Pheno Therapeutics
Per the firm's website.
Colleagues at Advent Life Sciences
Frequently asked questions
- Who is Fraser Murray?
- Fraser Murray is a drug discovery specialist and entrepreneur with nearly 30 years of experience in early drug development across pharma and biotech. In addition to serving as Head of Scientific Evaluation at Advent Life Sciences, he is CEO of portfolio company Pheno Therapeutics, and previously led Pandeia Therapeutics (acquired in December 2022), Chronos Therapeutics, and Polleo Pharma. He began his career at Merck's Neuroscience Research Centre and held roles at AstraZeneca and Shire; he studied Immunology and Pharmacology at the University of Strathclyde, earned a PhD in Neuropharmacology at the University of London, and completed an executive MBA at Alliance Manchester Business School.
- Where does Fraser Murray work?
- Fraser Murray is Head of Scientific Evaluation at Advent Life Sciences.
- What does Fraser Murray invest in?
- Fraser Murray invests in Biotech.
- What companies has Fraser Murray invested in?
- Investments tracked here include Pheno Therapeutics.